drugset / Trial / NCT02446990
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.
Timeline
- Start
- 2009-09
- Primary completion
- 2014-01
- Completion
- 2014-01
Publications
- Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.
- Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013 Oct;166(4):654-661.e6. doi: 10.1016/j.ahj.2013.06.024. Epub 2013 Sep 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivabradine | Small molecule | 5 mg | Oral |
| Subject | Ivabradine | Small molecule | 7.5 mg | Oral |
| Subject | Ivabradine | Small molecule | 10 mg | Oral |